- Home
- FBRX vs FTH Comparison
FBRX vs FTH Comparison
Compare FBRX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | FTH |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.4M | 835.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBRX | FTH |
|---|---|---|
| Price | $76.89 | $1,285.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 274.4K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.18 | $17.50 |
| 52 Week High | $77.20 | $37.90 |
Technical Indicators
Market Signals| Indicator | FBRX | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 84.38 | 61.17 |
| Support Level | $26.85 | $22.69 |
| Resistance Level | $77.20 | $36.94 |
| Average True Range (ATR) | 0.11 | 3.12 |
| MACD | -1.75 | 0.54 |
| Stochastic Oscillator | 88.64 | 70.15 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.